Topic Editors

Institute of Electronics, Bulgarian Academy of Sciences, 1784 Sofia, Bulgaria
Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria
Dr. Vesselin Kussovski
The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria

Porphyrinoids Photosensitizers for Biomedical Applications

Abstract submission deadline
closed (28 February 2023)
Manuscript submission deadline
closed (30 April 2023)
Viewed by
5044

Topic Information

Dear Colleagues,

The rapid spread of problems associated with drug resistance towards the present usage of chemotherapeutics necessitates the research and development of new natural and synthetic photosensitive compounds (photosensitizers) for biomedical applications. Well-known porphyrinoids such as porphyrins, phthalocyanines, and their related derivatives are of interest for the development of more effective original photosensitive molecules. Attempts to combine the best of their properties aim to facilitate optical diagnosis by fluorescence and local treatment owning to photosensitization. The curative method known as photodynamic therapy (PDT) has photodynamic action and has received research interest for more than a century. The scope of the present Topic is to collect the best of the recent developments made in the use of porphyrinoid photosensitizers in synthetic schemes, chemical and optical characterization, and the evaluation of photobiological properties as new-generation photosensitizers. We seek to collect novel studies conducted in the area of photochemistry science, as well as in photobiology research investigations, evaluations of their efficacy in PDT and fluorescent diagnosis, and in their application as theranostics agents. Original papers from prominent colleagues working in multidisciplinary areas of chemistry, biology, and biophysics will be highly appreciated.

Dr. Ivan Angelov
Dr. Vanya N. Mantareva
Dr. Vesselin Kussovski
Topic Editors

Keywords

  • photosensitizers
  • porphyrins
  • phthalocyanines
  • mechanisms of photosensitization
  • photophysics
  • photochemistry
  • photobiology
  • optical diagnosis
  • photodynamic therapy
  • theranostics

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Biology
biology
4.2 4.0 2012 18.7 Days CHF 2700
Biomolecules
biomolecules
5.5 8.3 2011 16.9 Days CHF 2700
Current Issues in Molecular Biology
cimb
3.1 2.4 1999 13.5 Days CHF 2200
International Journal of Molecular Sciences
ijms
5.6 7.8 2000 16.3 Days CHF 2900
Pharmaceuticals
pharmaceuticals
4.6 4.7 2004 14.6 Days CHF 2900

Preprints.org is a multidiscipline platform providing preprint service that is dedicated to sharing your research from the start and empowering your research journey.

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

  1. Immediately share your ideas ahead of publication and establish your research priority;
  2. Protect your idea from being stolen with this time-stamped preprint article;
  3. Enhance the exposure and impact of your research;
  4. Receive feedback from your peers in advance;
  5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (2 papers)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
17 pages, 2355 KiB  
Article
Alteration of Mesenchymal Stem Cells Isolated from Glioblastoma Multiforme under the Influence of Photodynamic Treatment
by Kalina Tumangelova-Yuzeir, Krassimir Minkin, Ivan Angelov, Ekaterina Ivanova-Todorova, Ekaterina Kurteva, Georgi Vasilev, Jeliazko Arabadjiev, Petar Karazapryanov, Kaloyan Gabrovski, Lidia Zaharieva, Tsanislava Genova and Dobroslav Kyurkchiev
Curr. Issues Mol. Biol. 2023, 45(3), 2580-2596; https://doi.org/10.3390/cimb45030169 - 21 Mar 2023
Cited by 1 | Viewed by 2494
Abstract
The central hypothesis for the development of glioblastoma multiforme (GBM) postulates that the tumor begins its development by transforming neural stem cells into cancer stem cells (CSC). Recently, it has become clear that another kind of stem cell, the mesenchymal stem cell (MSC), [...] Read more.
The central hypothesis for the development of glioblastoma multiforme (GBM) postulates that the tumor begins its development by transforming neural stem cells into cancer stem cells (CSC). Recently, it has become clear that another kind of stem cell, the mesenchymal stem cell (MSC), plays a role in the tumor stroma. Mesenchymal stem cells, along with their typical markers, can express neural markers and are capable of neural transdifferentiation. From this perspective, it is hypothesized that MSCs can give rise to CSC. In addition, MSCs suppress the immune cells through direct contact and secretory factors. Photodynamic therapy aims to selectively accumulate a photosensitizer in neoplastic cells, forming reactive oxygen species (ROS) upon irradiation, initiating death pathways. In our experiments, MSCs from 15 glioblastomas (GB-MSC) were isolated and cultured. The cells were treated with 5-ALA and irradiated. Flow cytometry and ELISA were used to detect the marker expression and soluble-factor secretion. The MSCs’ neural markers, Nestin, Sox2, and glial fibrillary acid protein (GFAP), were down-regulated, but the expression levels of the mesenchymal markers CD73, CD90, and CD105 were retained. The GB-MSCs also reduced their expression of PD-L1 and increased their secretion of PGE2. Our results give us grounds to speculate that the photodynamic impact on GB-MSCs reduces their capacity for neural transdifferentiation. Full article
Show Figures

Figure 1

17 pages, 5707 KiB  
Article
The In Vitro and In Vivo Anticancer Effect of Photomed for Photodynamic Therapy: Comparison with Photofrin and Radachlorin
by Jieun Kim, Johyun Kim, Heewon Yoon, Yoon-Jee Chae, Kiyon Rhew and Ji-Eun Chang
Curr. Issues Mol. Biol. 2023, 45(3), 2474-2490; https://doi.org/10.3390/cimb45030162 - 17 Mar 2023
Cited by 3 | Viewed by 1320
Abstract
To overcome the limitation of conventional cancer treatments, photodynamic therapy (PDT) has been introduced as another treatment option. PDT provides a non-invasive, non-surgical way with reduced toxicity. To improve the antitumor efficacy of PDT, we synthesized a novel photosensitizer, a 3-substituted methyl pyropheophorbide-a [...] Read more.
To overcome the limitation of conventional cancer treatments, photodynamic therapy (PDT) has been introduced as another treatment option. PDT provides a non-invasive, non-surgical way with reduced toxicity. To improve the antitumor efficacy of PDT, we synthesized a novel photosensitizer, a 3-substituted methyl pyropheophorbide-a derivative (Photomed). The purpose of the study was to evaluate the antitumor effect of PDT with Photomed comparing with the clinically approved photosensitizers Photofrin and Radachlorin. The cytotoxicity assay against SCC VII cells (murine squamous cell carcinoma) was performed to determine whether Photomed is safe without PDT and whether Photomed is effective against cancer cells with PDT. An in vivo anticancer efficacy study was also performed using SCC VII tumor-bearing mice. The mice were divided into small-tumor and large-tumor groups to identify whether Photomed-induced PDT is effective for not only small tumors but also large tumors. From in vitro and in vivo studies, Photomed was confirmed to be (1) a safe photosensitizer without laser irradiation, (2) the most effective photosensitizer with PDT against cancers compared to Photofrin and Radachlorin and (3) effective with PDT in treating not only small tumors but also large tumors. In conclusion, Photomed may contribute as a novel, potential photosensitizer for use in PDT cancer treatment. Full article
Show Figures

Figure 1

Back to TopTop